I-MAB (IMAB) Other Stockholders Equity : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Other Stockholders Equity?

I-MAB's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $0.00 Mil.

I-MAB's quarterly Other Stockholders Equity declined from Dec. 2023 ($-0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($0.00 Mil).

I-MAB's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

I-MAB Other Stockholders Equity Historical Data

The historical data trend for I-MAB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Other Stockholders Equity Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

I-MAB Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Other Stockholders Equity	Get a 7-Day Free Trial														-	-	-	-	-

I-MAB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

I-MAB Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of I-MAB's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).